Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 13

PMID 27518575

Citations 8

Authors

Elena Navarro-Villaran

Jose Tinoco

Granada Jimenez

Sheila Pereira

Jize Wang

Sara Aliseda

Maria A Rodriguez-Hernandez

Raul Gonzalez

Luis M Marin-Gomez

Miguel A Gomez-Bravo

Francisco J Padillo

Jose M Alamo-Martinez

Jordi Muntane

Affiliations

Soon will be listed here.

Abstract

Orthotopic liver transplantation (OLT) is the recommended treatment for patients at early stages of hepatocarcinoma (HCC) with potential portal hypertension and/or bilirubinemia, but without vascular-associated diseases. The patients are receiving immunosuppressive therapy to reduce graft rejection, but differential side effects have been related to calcineurin and mTOR inhibitor administration regarding tumor recurrence and nephrotoxicity. The in vitro studies showed that Tacrolimus exerted a more potent pro-apoptotic effect than Everolimus (Huh 7>Hep 3B>HepG2), being sirolimus only active in Hep3B cell line. Tacrolimus and Everolimus exerted potent antiproliferative properties in Huh 7 and Hep3B in which cells Sirolimus was inactive. Interestingly, Tacrolimus- and Everolimus-dependent G0/G1 cell accumulation occurred as a consequence of drastic reduction in S, as well as in S and G2+M phases, respectively. The in vivo studies support data on the more effective antitumoral properties of Everolimus, eventual risk of pro-angiogenic tumoral properties and nephrotoxicity of Tacrolimus, and pro-proliferative properties of Sirolimus in tumors developed in nude mice.

Citing Articles

Anti-viral and Apoptotic Induction of m-TOR Inhibitor Drugs against Hepatitis C Virus Activity and Hepatocellular Carcinoma Cell Line: In vitro and in silico.

Mofed D, Ahmed W, Mohaseb R, Rahouma M, Hassan Ibrahim Faraag A, Sabet S Asian Pac J Cancer Prev. 2024; 25(10):3725-3739.

PMID: 39471041 PMC: 11711332. DOI: 10.31557/APJCP.2024.25.10.3725.

Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi.

An L, Jia G, Tan J, Yang L, Wang Y, Li L Front Cell Infect Microbiol. 2023; 13:1131416.

PMID: 36909734 PMC: 9996166. DOI: 10.3389/fcimb.2023.1131416.

A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.

Saidy R, Wegener E, Uluk D, Dittrich L, Schoning W, Lurje G Medicina (Kaunas). 2022; 58(12).

PMID: 36556957 PMC: 9785597. DOI: 10.3390/medicina58121755.

Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center.

Kang S, Hwang S, Ha T, Song G, Jung D, Ahn C Korean J Transplant. 2022; 33(4):98-105.

PMID: 35769980 PMC: 9188937. DOI: 10.4285/jkstn.2019.33.4.98.

Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma.

Saidy R, Postel M, Pfluger M, Schoening W, Ollinger R, Gul-Klein S Cancers (Basel). 2021; 13(7).

PMID: 33807392 PMC: 8037838. DOI: 10.3390/cancers13071617.

References

Morton D, Griffiths P . Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Rec. 1985; 116(16):431-6. DOI: 10.1136/vr.116.16.431. View

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, OReilly T . The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120(6):747-59. DOI: 10.1016/j.cell.2004.12.040. View

Kawahara T, Kashiwagi E, Li Y, Zheng Y, Miyamoto Y, Netto G . Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. Mol Carcinog. 2015; 55(2):161-9. DOI: 10.1002/mc.22265. View

Wang T, Li B, Danielson P, Shah P, Rockwell S, Lechleider R . The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 1996; 86(3):435-44. DOI: 10.1016/s0092-8674(00)80116-6. View

Darzynkiewicz Z, Li X, Gong J . Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol. 1994; 41:15-38. DOI: 10.1016/s0091-679x(08)61707-0. View

McAlister V, Haddad E, Renouf E, Malthaner R, Kjaer M, Gluud L . Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006; 6(7):1578-85. DOI: 10.1111/j.1600-6143.2006.01360.x. View

Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E . Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res. 2011; 71(13):4573-84. DOI: 10.1158/0008-5472.CAN-10-4322. View

Workman P, Aboagye E, Balkwill F, Balmain A, Bruder G, Chaplin D . Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-77. PMC: 2883160. DOI: 10.1038/sj.bjc.6605642. View

10.

Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr J . Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005; 11(10):1420-5. PMC: 4305681. DOI: 10.3748/wjg.v11.i10.1420. View

11.

Rodriguez-Peralvarez M, Tsochatzis E, Naveas M, Pieri G, Garcia-Caparros C, OBeirne J . Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013; 59(6):1193-9. DOI: 10.1016/j.jhep.2013.07.012. View

12.

Sherr C . G1 phase progression: cycling on cue. Cell. 1994; 79(4):551-5. DOI: 10.1016/0092-8674(94)90540-1. View

13.

Siemann G, Blume R, Grapentin D, Oetjen E, Schwaninger M, Knepel W . Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. Mol Pharmacol. 1999; 55(6):1094-100. DOI: 10.1124/mol.55.6.1094. View

14.

Almawi W, Melemedjian O . Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant. 2000; 15(12):1916-8. DOI: 10.1093/ndt/15.12.1916. View

15.

Giordano A, Romano S, Mallardo M, DAngelillo A, Cali G, Corcione N . FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res. 2008; 79(3):519-26. DOI: 10.1093/cvr/cvn079. View

16.

Choi S, You H, Chung S . Tacrolimus-induced apoptotic signal transduction pathway. Transplant Proc. 2008; 40(8):2734-6. DOI: 10.1016/j.transproceed.2008.08.028. View

17.

Saunders P, Weiss J, Welschinger R, Baraz R, Bradstock K, Bendall L . RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine. Oncogene. 2012; 32(40):4789-97. DOI: 10.1038/onc.2012.498. View

18.

Liu H, Scholz C, Zang C, Schefe J, Habbel P, Regierer A . Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012; 32(5):1627-37. View

19.

Dumont F . FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem. 2000; 7(7):731-48. DOI: 10.2174/0929867003374723. View

20.

Tallon Aguilar L, Barrera Pulido L, Bernal Bellido C, Ciuro F, Suarez Artacho G, Alamo Martinez J . Causes and predisposing factors of de novo tumors in our series of liver transplant recipients. Transplant Proc. 2009; 41(6):2453-4. DOI: 10.1016/j.transproceed.2009.05.012. View